Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions

Autism Spectrum DisorderAnxiety

Interventions

DRUG

MB-IMP

MB-IMP is a marijuana-based investigational medical product. It contains a 23:1 ratio of CBD to THC, is an oil-based tincture that is taken orally.

OTHER

Placebo

Does not contain CBD or THC

Trial Locations (1)

Southwest Autism Research and Resource Center, Phoenix

All Listed Sponsors

lead

Southwest Autism Research & Resource Center

OTHER

NCT06526208 - Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults | Biotech Hunter | Biotech Hunter